Semaglutide vs Tirzepatide

Most drug comparisons are guesswork across separate trials with different populations, which is a poor way to decide anything. Semaglutide and tirzepatide are the rare case where a proper head-to-head study exists, so the efficacy question has an actual answer.

In SURMOUNT-5, tirzepatide produced an average weight loss of 20.2% against semaglutide's 13.7%. Participants on tirzepatide were also more likely to reach weight reductions of at least 10%, 15% and 20%. In the earlier SURPASS-2 trial in type 2 diabetes, tirzepatide at 5, 10 and 15 mg was noninferior and superior to semaglutide 1 mg.

So tirzepatide wins on average weight loss. But averages are not the whole decision — tolerability, cost, availability and what your insurance covers all matter, and for many people they matter more than the six-point difference.

How they actually differ

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone released after eating that slows gastric emptying, signals satiety to the brain and improves insulin response. Sold as Wegovy for weight management and Ozempic for type 2 diabetes, with Rybelsus and Wegovy tablets as oral forms.

Tirzepatide is a dual agonist. It acts on the GLP-1 receptor and also on the GIP (glucose-dependent insulinotropic polypeptide) receptor. That second pathway appears to add to the metabolic effect, which is the leading explanation for the larger average weight loss. Sold as Zepbound for weight management and Mounjaro for type 2 diabetes.

That single mechanistic difference — one receptor versus two — is what the entire comparison turns on. It is also why tirzepatide is sometimes described as a "GLP-1/GIP" rather than simply a GLP-1.

Side by side

Side effects: broadly similar, with differences of degree

Both drugs share the same side-effect profile because both act on the GLP-1 receptor. Gastrointestinal symptoms dominate: nausea, vomiting, diarrhea and constipation are by far the most common, with bloating and heartburn also frequently reported. Harvard Health describes GI symptoms as by far the most common effects of GLP-1 drugs generally.

On frequency, reported nausea rates vary widely across sources and study populations. One analysis puts semaglutide nausea in a broad 8% to 58% range and tirzepatide around 20%, which tells you more about how differently these things are measured than about a reliable difference between the drugs.

Both carry serious warnings, including pancreatitis. Wegovy's labelling instructs patients to stop the medication and contact their provider immediately for symptoms of pancreatitis — typically severe upper abdominal pain that may radiate to the back, often with fever and loss of appetite. Both also carry boxed warnings regarding thyroid C-cell tumours. Read the full prescribing information for whichever you are considering.

The practical management is the same for both: titrate slowly. Most GI effects appear or worsen after a dose increase and settle within a few weeks. A prescriber who is willing to slow your titration when you struggle is worth more than a small price difference.

When semaglutide may be the better choice

• You want an oral option. Semaglutide is available as Wegovy tablets and Rybelsus; there is no oral tirzepatide.
• Cost is the binding constraint. Wegovy tablets start at $149 a month self-pay through NovoCare Pharmacy, against $299 for the cheapest Zepbound dose.
• Your insurance covers Wegovy or Ozempic but not Zepbound — formulary position varies enormously between plans.
• You tolerated semaglutide well previously and see no reason to change.
• You want the option of a lower-intensity approach, since semaglutide's somewhat smaller average effect can suit people who found tirzepatide too much.

When tirzepatide may be the better choice

• Maximum weight loss is the priority. The head-to-head evidence is clear: 20.2% versus 13.7%.
• You want the best chance of reaching a 15% or 20% reduction — SURMOUNT-5 found tirzepatide participants more likely to hit those thresholds.
• You have plateaued on semaglutide at a maintenance dose and want to discuss switching with your prescriber.
• You have type 2 diabetes alongside obesity, where SURPASS-2 found tirzepatide superior to semaglutide 1 mg.
• You are on Medicare and the Zepbound KwikPen is covered under the GLP-1 Bridge program at $50 a month.

What the trial does not settle

An average is not a prediction for any individual. SURMOUNT-5 tells you that if you assigned a large group to each drug, the tirzepatide group would lose more on average. It does not tell you that you personally will lose more on tirzepatide — some people respond better to semaglutide, and real-world response varies considerably.

The trial also does not settle tolerability for you. A drug that produces 20% weight loss in people who stay on it is worth nothing if you cannot tolerate the titration. The most effective medication is always the one you can actually keep taking.

And it says nothing about access. If your insurance covers Wegovy at a $25 copay and Zepbound not at all, the six-point efficacy difference is unlikely to justify a $299-a-month cash outlay. Check your formulary before deciding on pharmacology alone.

Frequently Asked Questions

Keep Reading

Sources

Claims on this page trace to the following sources, checked on August 30, 2026.

• •Eli Lilly — SURMOUNT-5 head-to-head results, 20.2% vs 13.7%
• •NEJM — Tirzepatide versus semaglutide once weekly (SURPASS-2)
• •PubMed — Tirzepatide as compared with semaglutide for the treatment of obesity
• •Harvard Health — GLP-1 diabetes and weight-loss drug side effects
• •Wegovy — safety and side effects
• •Medicare.gov — Weight loss drugs coverage